Drug Profile
Adalimumab biosimilar - Shanghai Henlius Biotech
Alternative Names: Handayuan; HLX 03Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Shanghai Henlius Biotech
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Plaque psoriasis; Rheumatoid arthritis; Uveitis
Most Recent Events
- 29 Feb 2024 Preregistration for Ankylosing spondylitis (In children) in China (SC) before February 2024
- 29 Feb 2024 Preregistration for Plaque psoriasis (In children) in China (SC) before February 2024
- 29 Feb 2024 Preregistration for Rheumatoid arthritis (In children) in China (SC) before February 2024